



(51) International Patent Classification:

C07K 16/00 (2006.01) C07K 16/28 (2006.01)
C07K 16/06 (2006.01) C07K 16/30 (2006.01)
C12N 9/52 (2006.01) C07K 16/32 (2006.01)

(21) International Application Number:

PCT/US2021/050025

(22) International Filing Date:

13 September 2021 (13.09.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/078,254 14 September 2020 (14.09.2020) US

(71) Applicant: **SUTRO BIOPHARMA, INC.** [US/US]; 111
Oyster Point Blvd, South San Francisco, California 94080
(US).

(72) Inventor: **YIN, Gang**; c/o SUTRO BIOPHARMA, INC.,
111 Oyster Point Blvd, South San Francisco, California
94080 (US).

(74) Agent: **BORING, Landin F.** et al.; KILPATRICK
TOWNSEND & STOCKTON LLP, Mailstop: IP Docket-
ing - 22, 1100 Peachtree Street, Suite 2800, Atlanta, Georgia
30309 (US).

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(54) Title: METHOD FOR LARGE SCALE PRODUCTION OF ANTIBODIES USING A CELL-FREE PROTEIN SYNTHESIS SYSTEM




FIG. 1

(57) Abstract: Described herein are methods for large scale production of antibodies using a cell-free protein synthesis system. The methods include expressing a heavy chain (HC) polypeptide of an antibody from a nucleic acid encoding the heavy chain in a cell-free bacterial extract in the presence of a light chain (LC) polypeptide, thereby producing the antibody. The methods are performed at a large scale that is suitable for commercial production of antibodies, for example in a reaction volume equal to or greater than about 10 liters, for example about 10 to about 25,000 liters. The methods result in increased yields per unit volume of properly folded and assembled antibodies as opposed to synthesizing the light chain in the same cell-free protein synthesis system as the heavy chain polypeptide.

[Continued on next page]



(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*